RALTITREXED AND EDATREXATE DRUG MOLECULES AGAINST HUMAN PROTON COUPLED FOLATE TRANSPORTER TO CURE CANCER

Abstract

Proton pump inhibitors (PPIs) (e.g.: - rabeprazole, pantoprazole, omeprazole, lansoprazole, and esomeprazole) are widely used to treat gastroesophageal reflux disease and other acid-related disorders. Folic acid transport is important for proper cell proliferation. In human, folic acid is not synthesized in the body, it is obtained externally. Therefore, specific transporters are involved in absorption of folic acid, which is concentrated in intestine. Malignant cancer cells require this folic acid very frequently in large quantities for the rapid reproduction of cancer cell. In the current study, we compared different types of proton pump inhibitor drug molecules that may be potential candidates for preventing the absorption of folate by (hPCFT), its responsible for unusually large and frequent folate production. Each of these anti-drug candidates has 27 finalists based on previous studies. Among these competitors, leukovorin and noletraxid molecules were found to be particularly associated with the hPCFT transporter's key active site loop(G¹⁵⁵XXG¹⁵⁸).